Total drug treatment and comorbidity in myasthenia gravis: a population‐based cohort study
Autor: | Jone Furulund Owe, Nils Erik Gilhus, J. B. Andersen, Anders Engeland |
---|---|
Rok vydání: | 2014 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Population Co-morbidity VDP::Medisinske fag: 700::Helsefag: 800::Epidemiologi medisinsk og odontologisk statistikk: 803 Comorbidity Drug Prescriptions Cohort Studies Young Adult Pharmacotherapy Internal medicine medicine Humans VDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752 Medical prescription Child education Aged Aged 80 and over myasthenia gravis education.field_of_study VDP::Midical sciences: 700::Clinical medical sciences: 750::Neurology: 752 Norway business.industry Cme Article Middle Aged medicine.disease Myasthenia gravis Confidence interval drug therapy Surgery Neurology Pyridostigmine Cohort Female Drug therapy Neurology (clinical) VDP::Midical sciences: 700::Health sciences: 800::Epidemiology medical and dental statistics: 803 business Pyridostigmine Bromide medicine.drug |
Zdroj: | European Journal of Neurology |
ISSN: | 1468-1331 1351-5101 |
DOI: | 10.1111/ene.12439 |
Popis: | Background and purpose Comorbidity in myasthenia gravis (MG) is important for diagnosis, treatment and prognosis. Disease complexity was assessed by examining total drug treatment, immune therapy and comorbidity in a complete national MG cohort. Methods All recipients of the MG-specific drug pyridostigmine 2004–2010 registered in the compulsory Norwegian Prescription Database who met the inclusion criteria were included. The pyridostigmine group was compared with the general Norwegian population. Results Myasthenia gravis patients received co-medication more often than the controls for nearly all groups of medication, including insulins (95% confidence interval 2.0–3.7), thyroid therapy (1.7–2.5), antidepressants (1.3–1.7), anti-infectives (1.2–1.4), lipid-modifying agents (1.1–1.4) and immunomodulating agents (6.8–8.8). Conclusions Myasthenia gravis patients are more often treated with non-MG prescription drugs than controls, reflecting frequent co-medication and comorbidity. |
Databáze: | OpenAIRE |
Externí odkaz: |